C

A

CAPETTI , A.

Last name: CAPETTI

First name: A.

2016 (v1)

Publication

Metadata-only

Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial

Galli, Laura Spagnuolo, Vincenzo Bigoloni, Alba

Objectives: To report the 96 week results on efficacy, safety and bone mineral density (BMD) in subjects with HIV-1 that were virologically suppressed and treated with atazanavir/ritonavir monotherapy versus atazanavir/ ritonavir triple therapy. Methods: MODAt is a prospective, multicentre, open-label, non-inferiority, randomized, 96 week trial...

Uploaded on: May 13, 2023
2018 (v1)

Publication

Metadata-only

Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: a MODAt substudy

Merlini, Esther Galli, Laura Tincati, Camilla

No description

Uploaded on: February 4, 2024
2017 (v1)

Publication

Metadata-only

Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)

Di Giambenedetto, S. Fabbiani, M. Quiros Roldan, E.

Background: Combination ART (cART)-related toxicities and costs have prompted the need for treatment simplification. The ATLAS-M trial explored 48 week non-inferior efficacy of simplification to atazanavir/ritonavir + lamivudine versus maintaining three-drug atazanavir/ritonavir-based cART in virologically suppressed patients. Methods: We...

Uploaded on: April 14, 2023